Cure My Disease

Don't miss your cure!

 Log in / Sign up

New injection aims to stop dangerous psoriasis flares in their tracks

NCT ID NCT07314060

Disease control Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Aug 04, 2026 · Updated 3 times

Summary

This phase 2 trial tests an injection called TQH2929, a lab-made antibody that blocks inflammation, in 36 adults having a sudden, severe flare of generalized pustular psoriasis (GPP). Half get the drug, half get a placebo. The main goal is to see if the drug clears pustules within one week. Researchers also check for safety and longer-term skin clearing.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
TQH2929 injection (a lab-made antibody that blocks inflammation signals)
What this could lead to
If it works, this could point toward a fast-acting treatment for sudden, severe flare-ups of generalized pustular psoriasis.
What could go wrong
This is a small, early-phase trial with only 36 people. It may not show clear benefit, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

36 people

The number who actually took part.

Started

Mar 2026

Finished

Jul 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 or ≤75 years old at screening, regardless of gender; * Meet the diagnostic criteria defined by the 2017 European Society for Clinical Nutrition and Metabolism (ESPEN) Research Workshop (ERASPEN) consensus and be diagnosed as （generalized pustular psoriasis(GPP); * Compliant with GPP acute onset; * Able to read and understand, and willing to sign the informed consent form; * Willing and compliant with study visits and related procedures; * Female subjects of childbearing age should agree that contraceptive measures must be used during the study and for 6 months after the end of the study; Exclusion Criteria: * Pustules are limited to psoriasis vulgaris on psoriasis plaques; * Concomitant skin disease or medical disease that may interfere with the investigator's evaluation of the subject's treatment response; * Presence of severe, progressive, or uncontrolled disease, or signs and symptoms that are not suitable for participation in the investigator, in the judgment of the investigator: * Serum virological abnormalities during the screening period; * Chest radiology examination shows that the subject has active tuberculosis or a history of contact with open tuberculosis subjects in the past 6 months or a positive Interferon-Gamma Release Assays(IGRA) test; * History of serious infection leading to hospitalization within 2 months prior to baseline; * Active infection requiring systemic antibiotics, systemic antifungals, or systemic antiviral therapy within 2 weeks prior to baseline, according to the investigator's assessment; * History of opportunistic infection within 6 months prior to baseline; * Received live (attenuated) vaccine treatment within 12 weeks prior to baseline; * Any major surgery within 4 weeks prior to baseline or planned major surgery during the study; * Received blood transfusion within 4 weeks prior to baseline; * Participated in clinical trials of other drugs or medical devices within 4 weeks before baseline; * Any known or suspected congenital or acquired immunodeficiency state or condition that may compromise the subject's immune status; * Subjects with any type of active malignancy or a history of malignancy; * Alcohol, drug and known drug dependence; * Pregnant or lactating women; * Subjects cannot tolerate intravenous infusion administration.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Generalized pustular psoriasis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

generalized pustular psoriasis psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Generalized pustular psoriasis

Contacts and locations

Locations

  • Chengdu Second People's Hospital

    Chengdu, Sichuan, 610000, China

  • Henan Provincial People's Hospital

    Zhengzhou, Henan, 450003, China

  • Jiaxing First Hospital

    Jiaxing, Zhejiang, 314001, China

  • Peking University First Hospita

    Beijing, Beijing Municipality, 100034, China

  • Peking University Third Hospital

    Beijing, Beijing Municipality, 100191, China

  • People's Hospital of Xinjiang Uygur Autonomous Region

    Ürümqi, Xinjiang, 830001, China

  • Renmin Hospital of Wuhan University

    Wuhan, Hubei, 430060, China

  • Shandong First Medical University Affiliated Dermatology Hospital

    Jinan, Shandong, 250022, China

  • Shanghai Skin Disease Hospital

    Shanghai, Shanghai Municipality, 200443, China

  • Shiyan Renmin Hospital

    Shiyan, Hubei, 442000, China

  • Sichuan Provincial People' s Hospital

    Chengdu, Sichuan, 610000, China

  • Southern Medical University Dermatology Hospital

    Guangzhou, Guangdong, 510091, China

  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University

    Guangzhou, Guangdong, 510120, China

  • The Affiliated Hospital of Guizhou Medical University

    Guiyang, Guizhou, 550004, China

  • The Affiliated Hospital of Southwest Medical University

    Luzhou, Sichuan, 646000, China

  • The First Affiliated Hospital of Fujian Medical University

    Fuzhou, Fujian, 350000, China

  • The First Affiliated Hospital of Kunming Medical University

    Kunming, Yunnan, 650032, China

  • The First Affiliated Hospital of Xinjiang Medical University

    Ürümqi, Xinjiang, 830013, China

  • The First Hospital of Hunan University of Chinese Medicine

    Changsha, Hunan, 410007, China

  • The General Hospital Of Hunan University Of Medicine

    Huaihua, Hunan, 41800, China

  • The Second Affiliated Hospital of Henan University of science and technology

    Luoyang, Henan, 471000, China

  • The Second Affiliated Hospital of Xi'an Jiaotong University

    Xi’an, Shanxi, 710061, China

  • The Second Hospital Of Hebei Medical University

    Shijiazhuang, Hebei, 050000, China

  • The fifth Affiliated hospital of zhengzhou university

    Zhengzhou, Henan, 450052, China

  • The first affiliated hospital of ningbo university

    Ningbo, Zhejiang, 315020, China

  • The first hospital of china medical university

    Shenyang, Liaoning, 110001, China

  • The first hospital of jilin university

    Changchun, Jilin, 130012, China

  • Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital

    Tianjin, Tianjin Municipality, 300120, China

  • Tianjin Medical University General Hospital

    Tianjin, Tianjin Municipality, 300052, China

  • Xiangya Hospital of Central South University

    Changsha, Hunan, 410008, China

  • Zhengzhou Central Hospital

    Zhengzhou, Henan, 450000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.